Monobind
Private Company
Funding information not available
Overview
Monobind is a well-established, privately-held player in the global IVD market, with over four decades of experience in developing and manufacturing immunoassay reagents and instruments. The company operates on a business-to-business model, supplying kits, components, and instruments to clinical laboratories worldwide, and holds ISO 13485 certification for its quality management system. Its core strength lies in providing scalable, technology-agnostic diagnostic solutions across multiple platforms (microplate, monotest, magnetic bead, lateral flow, microarray) to meet diverse laboratory needs. With a broad product catalog and a global distribution footprint, Monobind is positioned as a reliable partner for routine and specialized diagnostic testing.
Technology Platform
Multi-format immunoassay platform specializing in ELISA and CLIA technologies, delivered in microplate, monotest, magnetic bead, lateral flow (LFA), and microarray systems.
Opportunities
Risk Factors
Competitive Landscape
Monobind competes in a fragmented but top-heavy market dominated by global giants like Abbott, Roche Diagnostics, Siemens Healthineers, and Danaher (Beckman Coulter, Radiometer). Its position is that of a specialized reagent and component supplier, competing on product quality, menu breadth, price, and flexibility against other mid-sized and private IVD companies (e.g., DiaSorin, bioMérieux in specific segments) and a multitude of smaller suppliers.